NTLA vs CRSP Stock Comparison: AI Score, Valuation, Performance and Upside
NTLA and CRSP are both leading CRISPR gene editing companies but with different strategic approaches — NTLA is furthest along in developing in vivo CRISPR therapies (directly editing cells inside the body), while CRSP has the first approved CRISPR therapy (ex vivo) and is now also developing in vivo programs. Intellia's in vivo data in ATTR amyloidosis has been particularly impressive clinically.
NTLA vs CRSP compares two CRISPR leaders at different points in their gene editing journeys, with Intellia advancing potentially transformative in vivo data and CRISPR Therapeutics leveraging its first-approved-therapy status into next-generation programs.
CRSP holds the edge across 3 of 5 key metrics in this comparison. CRSP has delivered stronger 1-year price return (-6.40% vs -21.62%), though NTLA has the better forward P/E setup (-4.90x vs -16.10x for CRSP). CRSP leads on both revenue growth (1041.40%) and operating margin (-1127.55%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for NTLA (+87.63%) than for CRSP (+55.54%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to the potential first approved in vivo CRISPR gene editing therapy
- Believe in vivo gene editing will ultimately address larger patient populations than ex vivo approaches
- Find Intellia's ATTR amyloidosis clinical data particularly compelling
- Value CRISPR Therapeutics' proven track record of bringing the first CRISPR therapy to approval
- Value the financial and commercial support from the Vertex partnership
- Want gene editing exposure with a commercially approved product rather than pre-commercial programs only
| Metric | NTLA | CRSP |
|---|---|---|
| AI scorei | 24.1 | 45.4 |
| AI ranki | #3309 | #699 |
| Latest closei | $12.22 | $58.33 |
| 1M returni | -4.83% | -1.97% |
| 6M returni | -6.79% | +24.42% |
| 1Y returni | -21.62% | -6.40% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | NTLA | CRSP |
|---|---|---|
| 1Y ago | $7.08K (-29.2%) started 2025-09-22 | $9.39K (-6.1%) started 2025-09-22 |
| 5Y ago | $827.13 (-91.7%) started 2021-09-21 | $4.97K (-50.3%) started 2021-09-21 |
| 10Y ago | $6.53K (-34.7%) started 2016-09-21 | $41.4K (+314.0%) started 2016-10-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | NTLA | CRSP |
|---|---|---|
| Market capi | $1.79B | $5.44B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -4.90 | -16.10 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 23.75 | 292.23 |
| Analyst targeti | $23.94 | $87.56 |
| Target upsidei | +87.63% | +55.54% |
| Metric | NTLA | CRSP |
|---|---|---|
| Revenue growthi | -46.20% | 1041.40% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | -419.83% | -1611.75% |
| Operating margini | -1472.26% | -1127.55% |
| Profit margini | 0.00% | 0.00% |
| ROIC proxyi | -55.44% | -26.10% |
| Return on equityi | -55.44% | -26.10% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.79 | 1.74 |
| Debt/equityi | 10.09 | 44.87 |
| Current ratioi | 6.65 | 17.85 |
| Quick ratioi | 5.61 | 17.79 |
Over the past year, NTLA and CRSP have moved moderately in the same direction (correlation of 0.67), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | NTLA | CRSP |
|---|---|---|---|
| 1Y | Growthi | -29.20% | -6.07% |
| CAGRi | -29.28% | -6.09% | |
| Volatilityi | 94.04% | 59.66% | |
| Sharpe ratioi | 0.09 | 0.12 | |
| Sortino ratioi | 0.12 | 0.17 | |
| Max drawdowni | 71.27% | 42.25% | |
| Current drawdowni | 56.33% | 24.03% | |
| Avg drawdowni | 50.32% | 27.67% | |
| Ulcer Indexi | 53.17% | 29.13% | |
| Max daily dropi | 42.23% | 11.59% | |
| Max wkly dropi | 52.63% | 18.19% | |
| 5Y | Growthi | -91.73% | -50.25% |
| CAGRi | -39.26% | -13.03% | |
| Volatilityi | 77.97% | 60.91% | |
| Sharpe ratioi | -0.30 | -0.00 | |
| Sortino ratioi | -0.42 | -0.00 | |
| Max drawdowni | 95.96% | 74.21% | |
| Current drawdowni | 92.13% | 51.89% | |
| Avg drawdowni | 77.12% | 52.97% | |
| Ulcer Indexi | 79.57% | 54.06% | |
| Max daily dropi | 42.23% | 13.32% | |
| Max wkly dropi | 52.63% | 21.49% | |
| 10Y | Growthi | -34.65% | +313.98% |
| CAGRi | -4.17% | +15.39% | |
| Volatilityi | 78.50% | 64.04% | |
| Sharpe ratioi | 0.28 | 0.47 | |
| Sortino ratioi | 0.41 | 0.73 | |
| Max drawdowni | 96.45% | 85.11% | |
| Current drawdowni | 93.09% | 72.23% | |
| Avg drawdowni | 56.48% | 49.91% | |
| Ulcer Indexi | 63.86% | 56.41% | |
| Max daily dropi | 42.23% | 17.10% | |
| Max wkly dropi | 52.63% | 30.47% |
| Category | NTLA | CRSP |
|---|---|---|
| Company | Intellia Therapeutics, Inc. | CRISPR Therapeutics AG |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Intellia Therapeutics focuses on developing in vivo CRISPR gene editing medicines — directly delivering gene editing tools into patients' bodies to correct disease-causing genetic mutations — with lead programs in ATTR amyloidosis and hemophilia A. | CRISPR Therapeutics developed Casgevy, the first FDA-approved CRISPR therapy (for sickle cell disease and beta-thalassemia), in partnership with Vertex Pharmaceuticals, while advancing next-generation in vivo programs in cardiovascular disease. |
| Investor focus | Investors track Intellia's pivotal clinical trial progress for NTLA-2001 (in vivo ATTR amyloidosis) and NTLA-2002, which could represent the first approved in vivo CRISPR therapies if successful. | Investors track Casgevy commercial ramp, next-generation in vivo cardiovascular programs, and the overall gene editing pipeline development supported by Vertex partnership funding. |
- Pioneer and potential leader in in vivo CRISPR gene editing, a potentially broader and simpler approach than ex vivo
- ATTR amyloidosis program (NTLA-2001) has shown impressive clinical data suggesting single-treatment durability
- Broadly licensed Cas9 platform from foundational Feng Zhang/MIT IP estate
- Only publicly traded gene editing company with a commercially approved CRISPR therapy (Casgevy)
- Well-funded through Vertex partnership with substantial cash runway
- Expanding into in vivo CRISPR programs that could address much larger patient populations than sickle cell/beta-thal
- All programs are still clinical-stage; no commercially approved products yet
- In vivo CRISPR delivery into the liver has been demonstrated but delivery into other tissues remains technically challenging
- Competing against strong ATTR amyloidosis drugs already approved (Alnylam, Ionis)
- Casgevy commercial adoption slower than initially expected due to treatment complexity
- Ex vivo gene editing approach is complex and resource-intensive for both patients and treatment centers
- In vivo programs are still early-stage and have not yet demonstrated clinical proof-of-concept
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.